Molecular switch identified by Duke-NUS researchers determines chemotherapy resistance in aggressive pancreatic cancer subtypes

Duke-NUS researchers identify GATA6 as the gene controlling pancreatic cancer's response to chemo. Blocking KRAS/ERK pathways can restore treatment sensitivity.

By: AXL Media

Published: Mar 4, 2026, 9:08 AM EST

Source: The information in this article was sourced from Duke-NUS Medical School

The challenge of subtype plasticity in pancreatic cancer

Pancreatic cancer remains a leading cause of cancer-related mortality due to its late-stage diagnosis and high rate of treatment resistance. Researchers at Duke-NUS Medical School have identified two primary molecular subtypes of the disease: classical and basal. The classical subtype is characterized by organized cellular structures and typically responds better to chemotherapy. Conversely, the basal subtype is disorganized, highly aggressive, and frequently resistant to standard medical interventions. A critical challenge for clinicians is "plasticity," the ability of cancer cells to shift between these two states, allowing a treatable tumor to transform into a lethal, drug-resistant form over time.

GATA6 as the master regulator of differentiation

The research team focused on GATA6, a gene that serves as the primary molecular switch for maintaining the organized classical state. When GATA6 expression remains high, pancreatic cancer cells retain a more structured form that is susceptible to existing drug regimens. However, when GATA6 levels are suppressed, the cells lose their organization and transition into the aggressive basal subtype. Professor David Virshup, the study's lead author, noted that while the medical community has long observed these state-switches, the specific mechanism driving the suppression of GATA6 was previously unknown. Identifying this gene's role provides a target for reversing resistance.

The KRAS and ERK signaling pathway

The study traced the suppression of GATA6 to a chain of intracellular signals initiated by the KRAS gene. Mutated in nearly all pancreatic cancer cases, KRAS sends constant growth signals through a partner protein called ERK. When this pathway becomes hyperactive, it triggers a cascade that effectively shuts down GATA6 production. This genetic silencing is what allows the cancer cells to lose their structure and gain chemo-resistance. Using advanced molecular analysis and genetic screening, the Duke-NUS team demonstrated that by blocking the KRAS and ERK signaling chain, they could lift the suppression on GATA6 and force the cells back into a more treatable state.